Journal of Neural Transmission

, Volume 108, Issue 2, pp 215–219

Long-term persistence of symptomatic effect of selegiline in parkinson’s disease, a two-months placebo-controlled withdrawal study

  • A. Negrotti
  • G. Bizzarri
  • S. Calzetti
Article

DOI: 10.1007/s007020170089

Cite this article as:
Negrotti, A., Bizzarri, G. & Calzetti, S. J Neural Transm (2001) 108: 215. doi:10.1007/s007020170089

Summary

Following a two-months of placebo-controlled withdrawal, the MAO-B inhibitor selegiline was found to maintain a long term significant mild to moderate symptomatic effect on bradykinesia and tremor at rest in nine patients with Parkinson’s disease (stage II and III of H⇐p;Y), whose functional impairment had also required a dopaminergic therapy with low-dose bromocriptine. Both motor signs found worsened during the wash-out showed a full recovery to pre-withdrawal condition within two months after reinstitution of the drug.

Keywords

SelegilineParkinson’s diseasewithdrawalsymptomatic effect

Copyright information

© Springer-Verlag 2001

Authors and Affiliations

  • A. Negrotti
    • 1
  • G. Bizzarri
    • 1
  • S. Calzetti
    • 1
    • 2
  1. 1.Istituto di NeurologiaUniversità di ParmaParmaItaly
  2. 2.Istituto di NeurologiaParmaItaly